C. Regarding the five oral route group (three hazardous medicines), reconstitution is required for three, which can be done in the PD. The other two are sold in sachets, so we plan to develop a handling protocol.
D. Directly proposed to prepare them in the PD.

Finally, we encourage implementing safe handling recommendations to achieve the goal of a safety plan for workers.

REFERENCES AND/OR ACKNOWLEDGEMENTS
We acknowledge all pharmacy and nursing staff.
No conflict of interest.

3PC-053 IMPACT OF SERIALISATION ON RECEPTION OF MEDICINES AND ACTIVITY SMOOTHING
P Lacassagne*, Intern in Pharmacy, 31270, Cugnaux, France
10.1136/ejhpharm-2020-eahpconf.100

Background and importance In February 2019, EU regulation 2016/161 made serialisation compulsory to improve the safety of medicines. This new regulation caused a major change in our practice of receiving medicines. Indeed, because of the high number of boxes received, we will install a robot to decommission all the medicine boxes.

Aim and objectives To identify the modifications in our reception process with the new regulation.

Material and methods Reception data on our managing software (Copilote) for the last 23 weeks were exported and analysed by Excel.

Results The new regulation will reorganise our process of reception by creating three different flows instead of one. The three identified flows are: serialisable+robot (SR); serialisable + no robot (SNR); not serialisable+ no robot (NSNR).

SR products will be handled by the robot whereas SNR will be decommissioned when received. We need to change our analysis method, from lines of product received to number of medicine boxes received, in order to assess the required volume of storage of our new robot. The main flow is SR (71%), followed by SNR (28.5%), whereas NSNR is negligible (0.5%). We observed that the number of drug boxes received was not smooth, with peak activity every 8 weeks.

Conclusion and relevance We identified the major changes caused by the new regulation and changed our analysis method to fit the new regulation. We will now analyse the largest laboratory orders to try to smooth out activity. Therefore, we will change the order calendar. Consequently, we expect an improvement in activity in order to stock the medicine boxes in the robot and reduce the delay in reception.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

3PC-054 SODIUM BENZOATE SUSPENSION IN NON-KETOTIC HYPERGLYCINAEMIA: A CASE REPORT
S Inmaulada, F Vallente Borrego*, M Muros, N Lucas, MA Sarabia, MA Rodriguez, J Ramos, J Alancon. Hospital De La Vega Lorenzo Guinao, Pharmacy, Murcia, Spain
10.1136/ejhpharm-2020-eahpconf.101

Background and importance Non-ketotic hyperglycinaemia (NKH) is a rare inborn error of glycine metabolism characterised by accumulation of glycine in body fluids and tissues, resulting in neurometabolic symptoms of variable severity. Sodium benzoate is the sodium salt of benzoic acid that conjugates with nitrogen containing glycine to form the molecule hippurate. Hippurate can be excreted by the kidneys, reducing plasma glycine levels. N-methyl-D-aspartate receptor antagonists may ameliorate neurological symptoms although it remains to be established whether they improve long term outcome. Lack of authorised presentations for treatment of rare diseases is an important obstacle that is usually resolved by hospital pharmacy formulations, especially in children.

Aim and objectives The aim was to provide an adequate, stable and well accepted oral sodium benzoate formulation for a patient with NKH, to improve her general status

Material and methods A 4-year-old girl with severe NKH needed oral treatment with sodium benzoate, although there is no standard oral formulation for children. To find an optimal and suitable solution, a literature search was carried out in the National Library of Medicine’s (MEDLINE) database, including terms ‘sodium benzoate/chemistry’, and ‘administration, oral’ with no other filter. Our national and regional formulation databases were also checked.

Results The patient was initially treated with 16 mL, three times a day, sodium benzoate syrup 112.5 mg/mL, but the volume needed was impossible to swallow by the patient due to her clinical status. Subsequently, 2 g sodium benzoate sachets were given with meals (four times a day) but they were not well tolerated.

We then dispensed a 250 mg/mL suspension in Oral-Sweet with a stability of 90 days. Despite it being a new formulation for our pharmacy service, glycine levels were reduced from 900–1000 μL/L to 500 μL/L over 2 months. Currently, her clinical situation is stable, and the patient receives 8 g/24 hours of sodium benzoate which is well tolerated.

Conclusion and relevance Sodium benzoate oral suspension dispensed with Oral-Sweet seemed to be an adequate solution to NKH treatment in our patient. Although the formulation is a basic operation for hospital pharmacy services, it is essential, especially in children with rare diseases that need orphan drugs.

REFERENCES AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

Section 4: Clinical Pharmacy Services

4CP-001 EXPERIENCE WITH THE NEW DIRECT ACTING ANTIVIRAL AGENTS IN A THIRD LEVEL HOSPITAL IN 2018
S Nuñez Bracamonte*, MH García Laguina, E Conesa Nicolás, A Lloret Llorca, C Juez Santamaría, CN García Matillas, I Fernández Martínez, JM Montoya Egea. Hospital General Universitario Santa Lucía, Farmacia Hospitalaria, Cartagena, Spain
10.1136/ejhpharm-2020-eahpconf.102

Background and importance The new direct acting antivirals (DAAs), indicated in chronic hepatitis C (HCV), show a sustained virological response at 12 weeks (SVR12) >90% in clinical trials, with worse results in patients with genotype 3.

Aim and objectives To analyse the effectiveness of the new DAAs in a real cohort of HCV patients during 2018, and establish if there are differences between genotypes.

Material and methods This was a retrospective observational study including all patients treated with DAAs in 2018. The